Fennec Pharmaceuticals Inc.
FRX.TO
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 38.79M | 33.30M | 30.91M | 47.54M | 49.35M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 38.79M | 33.30M | 30.91M | 47.54M | 49.35M |
| Cost of Revenue | 2.67M | 3.37M | 3.01M | 3.18M | 3.20M |
| Gross Profit | 36.12M | 29.94M | 27.91M | 44.35M | 46.15M |
| SG&A Expenses | 40.50M | 39.26M | 39.49M | 41.48M | 44.18M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.45M | 42.98M | 42.90M | 44.97M | 47.66M |
| Operating Income | -4.66M | -9.68M | -11.98M | 2.57M | 1.68M |
| Income Before Tax | -6.58M | -11.67M | -14.07M | -71.00K | -1.13M |
| Income Tax Expenses | 365.00K | 365.00K | 365.00K | 365.00K | -- |
| Earnings from Continuing Operations | -6.94 | -12.04 | -14.44 | -0.44 | -1.13 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.94M | -12.04M | -14.44M | -436.00K | -1.13M |
| EBIT | -4.66M | -9.68M | -11.98M | 2.57M | 1.68M |
| EBITDA | -4.56M | -9.58M | -11.88M | 3.37M | 4.28M |
| EPS Basic | -0.25 | -0.44 | -0.53 | -0.01 | -0.04 |
| Normalized Basic EPS | -0.15 | -0.26 | -0.32 | 0.00 | -0.02 |
| EPS Diluted | -0.26 | -0.45 | -0.54 | -0.08 | -0.10 |
| Normalized Diluted EPS | -0.15 | -0.26 | -0.32 | -0.04 | -0.06 |
| Average Basic Shares Outstanding | 110.59M | 110.07M | 109.71M | 109.17M | 108.55M |
| Average Diluted Shares Outstanding | 110.59M | 110.07M | 109.71M | 113.26M | 112.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |